Arrowhead to Present at Upcoming Conferences
05 October 2015 - 10:30PM
Business Wire
Arrowhead Research Corporation (NASDAQ: ARWR), a
biopharmaceutical company developing targeted RNAi therapeutics,
today announced that the company will present at the following
upcoming conferences.
Partnerships in Drug Delivery – Boston, October 5-6,
2015
October 6, 2:45 p.m. EDT – David Rozema,
Ph.D., vice president, chemistry will participate in a panel
discussion titled, “Can RNA-based therapeutics really
deliver?”
2015 International Meeting on Molecular Biology of Hepatitis
B – Dolce Bad Nauheim, Germany, October 4-8, 2015
October 7, 5:00-7:00 p.m. CET – Christine
Wooddell, Ph.D., group leader will deliver a poster presentation
titled, “Integrated HBV DNA significantly contributes to serum
HBsAg levels in chronically infected chimpanzees”
11th Annual Meeting of the Oligonucleotide
Therapeutics Society – Leiden, the Netherlands, October 11-14,
2015
October 14, 3:30 p.m. CET – Bruce Given,
M.D., chief operating officer will deliver an oral presentation
titled, “Development of RNAi-based therapeutics using DPC™
technology”
The Liver Meeting 2015®, 66th Annual Meeting of
the American Association for the Study of Liver Disease (AASLD)
– San Francisco, November 13-17, 2015
November 15, 3:15 p.m. PST – Christine
Wooddell, Ph.D., group leader will deliver an oral presentation
titled, “Reductions in cccDNA under NUC and ARC-520 therapy in
chimpanzees with chronic hepatitis B virus infection implicate
integrated DNA in maintaining circulating HBsAg”
November 17, 8:00 a.m. - 12:00 p.m. PST –
Christine Wooddell, Ph.D., group leader will deliver a poster
presentation titled, “Monthly dosing of ARC-520 in chronically
hepatitis B virus infected chimpanzees produces rapid, deep and
durable reductions in circulating viral antigens”
A copy of presentation materials, if available, can be accessed
by visiting the Events section of the company’s website at
http://ir.arrowheadresearch.com/events.cfm after the presentations
conclude.
About ARC-520
Arrowhead’s RNAi-based candidate ARC-520 is being investigated
in the treatment of chronic HBV infection. The small interfering
RNAs (siRNAs) in ARC-520 intervene at the mRNA level, upstream of
the reverse transcription process where current standard of care
nucleotide and nucleoside analogues act. Arrowhead is investigating
ARC-520 specifically, to determine if it can be used to achieve a
functional cure, which is an immune clearant state characterized by
hepatitis B s-antigen negative serum with or without
sero-conversion. Arrowhead has completed a Phase 1 single ascending
dose study in normal volunteers and the company is conducting
single dose Phase 2a studies and multiple dose Phase 2b studies in
chronic HBV patients. Approximately 350-400 million people
worldwide are chronically infected with the hepatitis B virus,
which can lead to cirrhosis of the liver and is responsible for 80%
of primary liver cancers globally.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company
developing targeted RNAi therapeutics. The company is leveraging
its proprietary Dynamic Polyconjugate™ delivery platform to develop
targeted drugs based on the RNA interference mechanism that
efficiently silences disease-causing genes. Arrowhead’s pipeline
includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver
disease associated with Alpha-1 antitrypsin deficiency, ARC-F12 for
hereditary angioedema and thromboembolic diseases, and ARC-HIF2 for
renal cell carcinoma.
For more information please visit
http://www.arrowheadresearch.com, or follow us on Twitter
@ArrowRes. To be added to the Company's email list and receive news
directly, please visit
http://ir.arrowheadresearch.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation
Reform Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those
expressed in any forward-looking statements as a result of various
factors and uncertainties, including our ability to finance our
operations, the future success of our scientific studies, our
ability to successfully develop drug candidates, the timing for
starting and completing clinical trials, rapid technological change
in our markets, and the enforcement of our intellectual property
rights. Arrowhead Research Corporation's most recent Annual Report
on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss
some of the important risk factors that may affect our business,
results of operations and financial condition. We assume no
obligation to update or revise forward-looking statements to
reflect new events or circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead
Research Corporation.
Source: Arrowhead Research Corporation
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151005005641/en/
Arrowhead Research CorporationVince Anzalone,
CFA626-304-3400ir@arrowres.comorInvestor Relations:The Trout
GroupChad Rubin646-378-2947ir@arrowres.comorMedia:Russo
PartnersMatt Middleman,
M.D.212-845-4272matt.middleman@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2024 to May 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From May 2023 to May 2024